Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma (Q64029840)

From Wikidata
Jump to navigation Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
clinical trial
Language Label Description Also known as
English
Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma
clinical trial

    Statements

    short name
    ReLive (English)
    0 references
    title
    Multicentre, Randomised, Controlled, Open-label Study Comparing the Efficacy and Safety of Slow Repeated IV Infusions of 2 Doses of Doxorubicin Transdrug™ (DT) (20mg/m2 and 30mg/m2) to Those of Best Standard of Care (BSC) in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure or Intolerance to Sorafenib. ReLive Study. (English)
    0 references
    country
    Austria
    0 references
    Belgium
    0 references
    Egypt
    0 references
    France
    0 references
    Germany
    0 references
    Hungary
    0 references
    Italy
    0 references
    Lebanon
    0 references
    Spain
    0 references
    Turkey
    0 references
    start time
    June 2012
    0 references
    end time
    September 2017
    0 references
    number of participants
    390
    0 references
    research intervention
    doxorubicin
    0 references
    Caelyx
    0 references
    minimum age
    18 year
    0 references

    Identifiers

     
                      Retrieved from "https://www.wikidata.org/w/index.php?title=Q64029840&oldid=2235239455"